MLSS MLSS
Company Profile ↓Company Overview
MLSS (MLSS) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $8.97M (+4.0% YoY); net profit $-5.72M.
- Trailing 12 Months Year-on-year growth — revenue +4.0%.
- 5-Year Trend Long-term compounding — revenue CAGR -0.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -0.55% |
| 1 Year: | 3.99% |
Stock Price Performance
| 1 Year: | -14.82% |
| 6 Months: | +73.52% |
| 3 Months: | +17.12% |
| 1 Month: | +37.79% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)64.40 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -0.5% CAGR over 5 years.
- Trading 27.9% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2013 | Jun 2013 | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.49M | - | - | 2.62M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 1.68M | 1.53M | 1.77M | 1.74M | 1.59M | 1.71M | 1.84M | 1.20M | 1.67M | 2.20M | 1.58M | 1.67M | 2.29M | 1.65M | 1.81M | 1.24M | 1.41M | -120.20K | 1.30M | 1.51M | 1.38M | 1.28M | 112.05K | 836.49K | 1.80M | 1.37M | 1.36M | 1.68M | 680.65K | 1.45M | 1.89M | 1.89M | 1.50M | 1.68M | 1.41M | 1.84M | 1.65M | 1.62M | 1.64M | 1.56M |
| Operating Income | 167.76K | 151.11K | 436.27K | 329.25K | 47.51K | -162.21K | -71.14K | -1.41M | -835.36K | -943.39K | -2.02M | -1.57M | -525.93K | -1.55M | -1.41M | -2.00M | -1.42M | -4.55M | -818.18K | -1.11M | -946.73K | -1.61M | -3.17M | -1.48M | -984.37K | -2.87M | -1.98M | -1.91M | -2.88M | -2.01M | -1.34M | -2.28M | -1.51M | -1.47M | -1.78M | -1.47M | -2.00M | -1.48M | -1.13M | -828.08K |
| Net Income | 150.75K | 74.01K | 218.52K | 194.83K | -169.46K | -358.49K | -419.38K | -2.07M | -1.57M | -750.06K | -1.59M | -1.70M | -504.87K | -1.48M | -1.41M | -1.87M | -1.34M | -4.39M | -782.75K | -1.04M | -2.84M | -1.60M | -3.17M | -1.49M | -972.87K | -2.68M | -2.04M | -1.90M | -2.86M | -1.97M | -1.31M | -2.22M | -1.47M | -1.44M | 223.64K | -1.46M | -1.99M | -1.48M | -1.15M | -839.85K |
| Diluted EPS | 0.01 | 0.00 | 0.01 | 0.01 | -0.01 | -0.02 | -0.02 | -0.09 | -0.07 | -0.03 | -0.06 | -0.06 | -0.02 | -0.05 | -0.04 | -0.06 | -0.04 | -0.12 | -0.02 | -0.02 | -0.06 | -0.03 | -0.06 | -0.02 | -0.01 | -0.04 | -0.03 | -0.03 | -0.04 | -0.03 | - | - | - | - | - | -0.02 | -0.02 | - | -0.01 | -0.01 |
| R&D Expense | 121.84K | 42.88K | 12.70K | 15.72K | 29.16K | 29.37K | 10.12K | 18.82K | 20.68K | 143.44K | 309.33K | 303.27K | 105.02K | 120.06K | 16.88K | 225.82K | 9.78K | 1.50K | 6.35K | 95.53K | 7.94K | 107.48K | 108.17K | 21.44K | 16.44K | 215.42K | 356.18K | 464.47K | 266.56K | 166.19K | 140.35K | 213.65K | 170.48K | 94.21K | 314.97K | 232.06K | 369.12K | 51.79K | 16.23K | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.75M | 8.38M | 8.65M | 10.01M | 10.33M | 9.49M | 10.48M | 11.28M | 9.62M | 8.37M | 5.44M | 10.30M | 8.81M | 9.83M | 8.63M | 8.97M |
| Gross Profit | 6.22M | 5.36M | 5.59M | 6.81M | 6.70M | 6.44M | 6.31M | 6.97M | 4.43M | 5.72M | 3.62M | 6.31M | 4.90M | 6.79M | 6.43M | 6.41M |
| Operating Income | -700.84K | -1.22M | -520.35K | 1.09M | -790.18K | -3.06M | -6.51M | -5.23M | -8.00M | -4.00M | -7.45M | -7.38M | -8.83M | -7.11M | -6.76M | -5.70M |
| Net Income | -614.51K | -1.48M | -870.31K | 1.46M | -1.70M | -5.47M | -5.95M | -5.19M | -7.43M | -7.52M | -7.34M | -6.82M | -8.71M | -6.93M | -4.71M | -5.72M |
| Diluted EPS | - | - | -0.05 | 0.08 | -0.08 | -0.26 | -0.22 | -0.16 | -0.21 | -0.16 | -0.12 | -0.10 | - | - | -0.06 | -0.07 |
| R&D Expense | 270.49K | 140.05K | 181.98K | 191.34K | 88.24K | 100.86K | 1.27M | 272.75K | 245.64K | 189.92K | 307.85K | 878.21K | 1.15M | 701.38K | 858.77K | 449.47K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 6.61M | 6.99M | 5.66M | 8.06M | 17.48M | 12.81M | 14.18M | 15.63M | 6.40M | 6.56M | 19.57M | 19.81M | 13.70M | 11.37M | 9.80M | 7.81M |
| Total Equity | 2.64M | 2.33M | 1.94M | 1.94M | 5.52M | 14.65M | 10.31M | 8.50M | 7.24M | 1.54M | 1.70M | 16.20M | 16.37M | 10.23M | 8.01M | 5.83M | 2.81M |
| Cash & Equivalents | 1.03M | 627.08K | 96.32K | 165.25K | 1.15M | 10.37M | 4.19M | 3.60M | 2.64M | 743.43K | 1.52M | 14.22M | 14.76M | 8.72M | 2.98M | 3.26M | 1.11M |
| Total Liabilities | - | - | - | - | 2.54M | 2.49M | - | 5.65M | 8.13M | 4.87M | 4.93M | 3.46M | 3.59M | 3.70M | 3.36M | 3.96M | 4.99M |
| Current Liabilities | - | 3.39M | 4.61M | 3.27M | 2.54M | 2.44M | 3.64M | 5.65M | 6.73M | 4.87M | 4.93M | 2.88M | 3.10M | 3.30M | 3.08M | 3.74M | 4.13M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -293.78K | -570.73K | -49.72K | 1.26M | - | - | -5.40M | -1.23M | -1.63M | -1.78M | -6.98M | -4.03M | -6.03M | -5.33M | -2.92M | -2.92M |
| Investing Cash Flow | -108.27K | -39.03K | -31.36K | -561.39K | - | - | 8.21K | -199.18K | -15.42K | -9.92K | -21.44K | -15.19K | -8.53K | -2.97M | 2.97M | -15.12K |
| Financing Cash Flow | - | 79.00K | 150.00K | 284.60K | - | - | 4.80M | 463.34K | -250.00K | 2.56M | 19.71M | 4.59M | -8.54K | 2.56M | 233.77K | 786.34K |
| Capital Expenditure | -29.36K | -7.47K | -4.74K | -5.54K | -82.21K | -67.58K | -15.34K | -6.01K | -7.40K | -9.92K | -21.44K | -15.19K | -8.53K | - | -10.12K | -15.12K |
| Free Cash Flow | -323.13K | -578.20K | -54.45K | 1.25M | - | - | -5.41M | -1.24M | -1.64M | -1.79M | -7.01M | -4.05M | -6.04M | - | -2.93M | -2.93M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 63.8% | 64.0% | 64.7% | 68.0% | 64.9% | 67.9% | 60.2% | 61.8% | 46.1% | 68.3% | 66.6% | 61.3% | 55.7% | 69.1% | 74.6% | 71.4% |
| Operating Margin % | -7.2% | -14.6% | -6.0% | 10.9% | -7.6% | -32.2% | -62.1% | -46.4% | -83.1% | -47.8% | -137.1% | -71.6% | -100.2% | -72.3% | -78.3% | -63.5% |
| Net Margin % | -6.3% | -17.7% | -10.1% | 14.6% | -16.5% | -57.6% | -56.7% | -46.0% | -77.2% | -89.8% | -134.9% | -66.2% | -98.9% | -70.5% | -54.6% | -63.8% |
| ROE % | -26.3% | -76.5% | -44.9% | 26.5% | -11.6% | -53.0% | -70.0% | -71.6% | -482.7% | -443.7% | -45.3% | -41.7% | -85.1% | -86.5% | -80.8% | -203.4% |
| ROCE % | -21.8% | -51.3% | -21.8% | 19.7% | -5.3% | -33.4% | -76.3% | -58.8% | -523.4% | -245.5% | -44.6% | -44.1% | -84.9% | -85.7% | -111.6% | -155.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MLSS
Epidural Device to Be Marketed Across VA and Military Systems - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxPMnB5V1lGWV91Nld1QVBVWnRJaW56eTVIaU5XMHM0MmRTOThQVzlxczRpbmpwNllCNGJRMHowVmtSM3ZTS3hUb3RXakloUTl1U2hWU0RhRVVYVjBZLUo5MXFYU2ZGNEdzN09GRkF1SG5zQXA3NC1keWkyNlo3QXYyUnZ3Zmc3YkZZTzJRZU…
MLSS|Milestone Scientific Inc|Price:0.470|Chg%:+0.035 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE5JNDJ0RW5nWDZERGotWXcwaXR5YlprUkROUktad3VGTUFKNFZZcC1VTXZGcldsRzZJRzJMV3RRQWRxbkJ5NUlOb2VUczU5M2FXU1FkT1BRV25FOXpqTUtFNVcxd2FLbm13VW02TnFn?oc=5" target="_blank">MLSS|Milestone Scie…
Milestone Scientific Inc. (NYSE: MLSS) investors back higher share and equity plan limits - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxNcEdNWHZ1X2RzSGRlMml4VkdsbzhJaWg2cGh0c25XZi1JUnJNT051X015UWZ4RFJUZGVTZEdWcWM1TmRDMDBwU3J4bk5COXl6UHVCcHZCNVlZOGF4UDNYNkhKaXdNRzBnUkp3aDQ0bzI0WF9JTmwyZ1R1WENMeTRxUlZHc080UGJ2SlZlem…
Milestone Scientific directors elect conversion of remaining bridge notes pending $0.50 fair value - TradingView
<a href="https://news.google.com/rss/articles/CBMi8AFBVV95cUxOLTRnUy1EQ3kxQ1BvQmZ6eE9HYV9ZTXFjMm5RbnpqWTMtMUFnYldqUHBnYklPVTNkbkJjNmhXZDBRazBhSFB2UHo0dHlyMENJZEdjVkt3Q2NMU3BBN2djS2ZRY0FDMjZVYmRzU1RRQnozNDJaS28wODZKcGFhWlpvSmt6ZFl6azd5OFRiVT…
Milestone Scientific Restructures Leadership and Governance Agreements - theglobeandmail.com
<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxOTXRxMEJJdW1JdkIzTUZTZzNKdTJIaVpqYnZ3czVmeWNEemxXbG56dU5nbGR0LWhkN2wwbWZWa1o1T3UtOHozQ2NfcVdrby1uS085d3d4OU1TV2I1ME9EekEybHUzT2cxdmQyVy1rc3BfOS0xdHIzNnA5bUxIYlpMTkxBM2NNaTFJa0owS1…
Benchmark reiterates Milestone Scientific stock Speculative Buy on Q2 beat - Investing.com
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxPM2Q0RndJMGFVUE9rQS1PTW03M3dleUVoUlFKNHN6T0hKc3VSNThYMlc3dXN4Qmg0TmFVeWFFLUIwT3RGUGVPSWlJdHNhaUUwcHU5MmNRUTlQSkk4cktIeTd0Y1BLd2RCclZPYVVwYnl3RVhHNC1sMmplUVlXYXUtTDgwRnBUYWo2Z21HQk…
MLSS — Frequently Asked Questions
What is the current share price of MLSS?
As of 2026-08-05 17:25 PDT, MLSS trades at $0.47 on NASDAQ/NYSE. Its 52-week range is $0.25 to $0.65.
What is the P/E ratio of MLSS?
MLSS trades at a trailing price-to-earnings (P/E) ratio of -6.71.
Is MLSS a good stock to buy?
This page provides a data-driven analysis of MLSS, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.